



17010477



William Slattery, CFA
Vice President
Listing Qualifications

Received SEC

MAY 03 2017

Washington, DC 20549

CERT NAS

File No. 001-38079

Electronic Mail Only

May 3, 2017

Mr. Jeffrey Thomas
Chief, IT Services
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on May 1, 2017 The Nasdaq Stock Market (the "Exchange") received from UroGen Pharma Ltd. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Ordinary Shares, par value NIS 0.01 per

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Slattery